Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity

The gut microbiota is a newly identified contributor to the development of non-alcoholic fatty liver disease (NAFLD). Previous studies of Bifidobacterium adolescentis (B. adolescentis), a species of Bifidobacterium that is common in the human intestinal tract, have demonstrated that it can alleviate liver steatosis and steatohepatitis. Fibroblast growth factor 21 (FGF21) has long been considered as a biomarker of NAFLD, and recent studies have shown the protective effect of FGF21 analogs on NAFLD. We wondered whether B. adolescentis treatment would alleviate NAFLD via the interaction with FGF21. To this end, male C57BL/6J mice on a choline-deficient high-fat diet (CDHFD) were treated with drinking water supplemented with B. adolescentis for 8 weeks, followed by the acute administration of recombinant mouse FGF21 protein (rmFGF21) to conduct the FGF21 response test. Consistent with previous studies, B. adolescentis supplementation reversed the CDHFD-induced liver steatosis and steatohepatitis. This was evaluated on the NAFLD activity score (NAS), reduced liver enzymes, and lipid accumulation. Further studies demonstrated that B. adolescentis supplementation preserved the gut barrier, reduced the gut microbiota-derived lipopolysaccharide (LPS), and inhibited the hepatic TLR4/NF-κB pathway. This was accompanied by the elevated expressions of the receptors of FGF21, fibroblast growth factor receptor 1 (FGFR1) and β-klotho (KLB), in the liver and the decreased expression of FGF21. The results of FGF21 response test showed that B. adolescentis supplementation alleviated the CDHFD-induced FGF21 resistance. In vivo experiments suggested that LPS could suppress the expression of FGF21 and KLB in a dose-dependent manner. Collectively, this study showed that B. adolescentis supplementation could alleviate NAFLD by increasing FGF21 sensitivity.

[1]  M. Noman,et al.  Fibroblast Growth Factor 21 Augments Autophagy and Reduces Apoptosis in Damaged Liver to Improve Tissue Regeneration in Zebrafish , 2021, Frontiers in Cell and Developmental Biology.

[2]  M. Rescigno,et al.  The gut vascular barrier: a new player in the gut-liver-brain axis. , 2021, Trends in molecular medicine.

[3]  Wei Chen,et al.  Bifidobacterium adolescentis Isolated from Different Hosts Modifies the Intestinal Microbiota and Displays Differential Metabolic and Immunomodulatory Properties in Mice Fed a High-Fat Diet , 2021, Nutrients.

[4]  Matthew J. Potthoff,et al.  Metabolic Messengers: FGF21 , 2021, Nature Metabolism.

[5]  M. Grajower.  Nonalcoholic Steatohepatitis. , 2020, JAMA.

[6]  A. Sgoifo,et al.  Bifidobacterium adolescentis as a key member of the human gut microbiota in the production of GABA , 2020, Scientific Reports.

[7]  L. Vitetta,et al.  Probiotics and synbiotics targeting the intestinal microbiome attenuate non-alcoholic fatty liver disease. , 2020, Hepatobiliary surgery and nutrition.

[8]  Xiaokun Li,et al.  Disruption of FGF Signaling Ameliorates Inflammatory Response in Hepatic Stellate Cells , 2020, Frontiers in Cell and Developmental Biology.

[9]  M. Izquierdo,et al.  Assessment of dietary supplementation with galactomannan oligosaccharides and phytogenics on gut microbiota of European sea bass (Dicentrarchus Labrax) fed low fishmeal and fish oil based diet , 2020, PloS one.

[10]  S. Ikramuddin,et al.  Nonalcoholic Steatohepatitis: A Review. , 2020, JAMA.

[11]  J. Kemper,et al.  Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase , 2020, Nature Communications.

[12]  S. Rabot,et al.  Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease , 2020, mBio.

[13]  G. Carpino,et al.  Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD , 2019, Hepatology.

[14]  M. Gorrell.  Faculty Opinions recommendation of Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[15]  H. Yoshiji,et al.  Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model , 2019, International journal of molecular sciences.

[16]  R. Yu,et al.  Exopolysaccharide-Producing Bifidobacterium adolescentis Strains with Similar Adhesion Property Induce Differential Regulation of Inflammatory Immune Response in Treg/Th17 Axis of DSS-Colitis Mice , 2019, Nutrients.

[17]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[18]  B. Neuschwander‐Tetri,et al.  Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial , 2018, The Lancet.

[19]  Matthew J. Potthoff,et al.  Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis. , 2018, Annual review of nutrition.

[20]  Xiangdong Gao,et al.  A long‐acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non‐alcoholic steatohepatitis partly through an FGF21‐adiponectin‐IL17A pathway , 2018, British journal of pharmacology.

[21]  P. Gentileschi,et al.  Molecular Phenomics and Metagenomics of Hepatic Steatosis in Non-Diabetic Obese Women , 2018, Nature Medicine.

[22]  S. Cha,et al.  Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways , 2018, Gut and liver.

[23]  M. Reis,et al.  Changes in mouse gut bacterial community in response to different types of drinking water. , 2018, Water research.

[24]  anonymous.  In Review , 2018 .

[25]  Shibu Yooseph,et al.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. , 2017, Cell metabolism.

[26]  T. Odamaki,et al.  Differences between live and heat-killed bifidobacteria in the regulation of immune function and the intestinal environment. , 2017, Beneficial microbes.

[27]  H. Deng,et al.  Fasting-induced hormonal regulation of lysosomal function , 2017, Cell Research.

[28]  Matthew J. Potthoff,et al.  FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. , 2017, Cell metabolism.

[29]  Matthew J. Potthoff,et al.  FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue , 2017, Molecular metabolism.

[30]  C. Benoist,et al.  Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice , 2016, Proceedings of the National Academy of Sciences.

[31]  Liying Song,et al.  Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. , 2016, International immunopharmacology.

[32]  Mengwei Zang,et al.  Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice , 2016, Hepatology.

[33]  A. Xu,et al.  Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe −/− Mice , 2016, Circulation.

[34]  Hui Zhao,et al.  IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes. , 2016, American journal of physiology. Endocrinology and metabolism.

[35]  S. Bischoff,et al.  Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. , 2014, The Journal of nutritional biochemistry.

[36]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[37]  S. Kliewer,et al.  βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. , 2012, Cell metabolism.

[38]  F. Villarroya,et al.  TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. , 2012, Endocrinology.

[39]  Jinjin Chen,et al.  Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome , 2011, British Journal of Nutrition.

[40]  B. Spiegelman,et al.  Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. , 2011, Endocrinology.

[41]  S. Rabot,et al.  Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  K. Xiang,et al.  Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. , 2010, Journal of hepatology.

[43]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[44]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[45]  S. Kliewer,et al.  Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21* , 2007, Journal of Biological Chemistry.

[46]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[47]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.